Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 Oct;9(5 Suppl):S72-83.
doi: 10.1016/j.jalz.2012.10.007. Epub 2013 Jan 30.

Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging

Keith A Johnson  1 , Reisa A Sperling, Christopher M Gidicsin, Jeremy S Carmasin, Jacqueline E Maye, Ralph E Coleman, Eric M Reiman, Marwan N Sabbagh, Carl H Sadowsky, Adam S Fleisher, P Murali Doraiswamy, Alan P Carpenter, Christopher M Clark, Abhinay D Joshi, Ming Lu, Michel Grundman, Mark A Mintun, Michel J Pontecorvo, Daniel M Skovronsky; AV45-A11 study group
Collaborators, Affiliations
Clinical Trial

Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging

Keith A Johnson et al. Alzheimers Dement. 2013 Oct.

Abstract

Objective: To evaluate the performance characteristics of florbetapir F18 positron emission tomography (PET) in patients with Alzheimer's disease (AD), mild cognitive impairment (MCI), and healthy control subjects (HCs).

Methods: Florbetapir PET was acquired in 184 subjects (45 AD patients, 60 MCI patients, and 79 HCs) within a multicenter phase 2 study. Amyloid burden was assessed visually and quantitatively, and was classified as positive or negative.

Results: Florbetapir PET was rated visually amyloid positive in 76% of AD patients, 38% of MCI patients, and 14% of HCs. Eighty-four percent of AD patients, 45% of MCI patients, and 23% of HCs were classified as amyloid positive using a quantitative threshold. Amyloid positivity and mean cortical amyloid burden were associated with age and apolipoprotein E ε4 carrier status.

Conclusions: : The data are consistent with expected rates of amyloid positivity among individuals with clinical diagnoses of AD and MCI, and indicate the potential value of florbetapir F18 PET as an adjunct to clinical diagnosis.

Keywords: Alzheimer's disease; Amyloid; Amyvid; Florbetapir; Mesh; PET.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mean Cortical SUVr by diagnostic group and ApoE ε4 status
Figure 2
Figure 2
Mean Cortical SUVr in Healthy Controls by age
Figure 3
Figure 3
Average Mean Cortical SUVr by APOE ε4 genotype and diagnostic group. Error bars show the upper 95% CI using the standard error of the mean.
See this image and copyright information in PMC

References

    1. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch. Neurol. 2008;65:1509–1517. Aizenstein 2008. - PMC - PubMed
    1. Becker JA,, Hedden T, Carmasin J, Maye J, Rentz DM, Putcha D, Fischl B, Greve D, Marshall G, Salloway S, Marks D, Buckner RL, Sperling RA, Johnson KA. Amyloid-Associated Cortical Thinning in Clinically Normal Elderly. Annals of Neurology. 2010 - PMC - PubMed
    1. Bacskai BJ, Frosch MP, Freeman SH, et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case re port. Arch Neurol. 2007;64:431–434. - PubMed
    1. Bennett DA, Schneider JA, Bienias JL, Evans Dam Wuksib RS. Mild cognitive impairment is related to Alzheimer’s disease pathology and cerebral infarctions. Neurology. 2005;64(5):834–841. - PubMed
    1. Braak H, Braak E. Diagnostic criteria for neuropathologic assessment of Alzheimer’s disease. Neurobiol Aging. 1997;18(suppl):S85–S88. - PubMed

Publication types

Substances